BRIACELL THERAPEUTICS CORP. — Operating Income by Fiscal Year
5 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/d4968f7e-4eb4-45f4-94e6-419a0ca2ae4a/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-27.2M | 2024-08-01 – 2025-07-31 | evidence 0001493152-25-018212 |
| FY 2024 | $-33.3M | 2023-08-01 – 2024-07-31 | evidence 0001493152-24-042743 |
| FY 2023 | $-23.3M | 2022-08-01 – 2023-07-31 | evidence 0001493152-23-038298 |
| FY 2022 | $-15.3M | 2021-08-01 – 2022-07-31 | evidence 0001493152-22-029742 |
| FY 2021 | $-7.0M | 2020-08-01 – 2021-07-31 | evidence 0001493152-22-029742 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).